Why the study?
Does the addition of calcium channel blockers to renin-angiotensin axis-blocking drugs reduce the progression of chronic kidney disease and cardiovascular events compared to the addition of hydrochlorothiazide in patients with systolic hypertension and renal disease?
Does the addition of calcium channel blockers to renin-angiotensin axis-blocking drugs reduce the progression of chronic kidney disease and cardiovascular events compared to the addition of hydrochlorothiazide in patients with systolic hypertension and renal disease?
Evidence supports the recommendation of using calcium channel blockers as the preferred second antihypertensive agent added to renin-angiotensin axis-blocking drugs to prevent renal disease progression.
The Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial showed that initial antihypertensive therapy with benazepril plus amlodipine was superior to benazepril plus hydrochlorothiazide in reducing progression of chronic kidney disease as well as cardiovascular morbidity and mortality in renal patients. The renal results of the ACCOMPLISH trial strongly support the recommendation of using calcium channel blockers as second antihypertensive agent added to renin-angiotensin axis-blocking drugs. This review discusses the validity of these data and their relationship with the cumulative evidence on the effects of calcium antagonists on renal disease progression.
No takes yet. Share an insight, caveat, or question.
Robles et al. (2012) conducted a review in Systolic hypertension and renal disease. Benazepril plus amlodipine vs. Benazepril plus hydrochlorothiazide was evaluated on Progression of chronic kidney disease as well as cardiovascular morbidity and mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: